Unity Biotechnology Inc.

0.99
0.01 (0.64%)
At close: Apr 25, 2025, 3:59 PM
0.97
-1.53%
After-hours: Apr 25, 2025, 04:43 PM EDT

Company Description

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging.

The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.

It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications.

The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015.

Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Unity Biotechnology Inc.
Unity Biotechnology Inc. logo
Country United States
IPO Date May 3, 2018
Industry Biotechnology
Sector Healthcare
Employees 16
CEO Dr. Anirvan Ghosh Ph.D.

Contact Details

Address:
285 East Grand Avenue
South San Francisco, California
United States
Website https://unitybiotechnology.com

Stock Details

Ticker Symbol UBX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001463361
CUSIP Number 91381U101
ISIN Number US91381U2006
Employer ID 26-4726035
SIC Code 2834

Key Executives

Name Position
Dr. Anirvan Ghosh Ph.D. Chief Executive Officer & Director
Alexander Hieu Nguyen J.D. Chief Legal Officer & Head of Operations
Alicia Tozier M.B.A. Chief Strategy Officer
Dr. Federico Grossi M.D., Ph.D. Chief Medical Officer
Dr. Jan M. van Deursen Ph.D. Founder
Dr. Nathaniel E. David A.B., Ph.D. Co-Founder & Independent Director
Dr. Przemyslaw Sapieha Ph.D. Chief Scientist

Latest SEC Filings

Date Type Title
Apr 22, 2025 10-Q Quarterly Report
Apr 22, 2025 8-K Current Report
Apr 11, 2025 10-K/A [Amend] Annual Report
Apr 04, 2025 8-K Current Report
Apr 03, 2025 4 Filing
Apr 03, 2025 4 Filing
Apr 03, 2025 4 Filing
Mar 31, 2025 4 Filing
Mar 31, 2025 4 Filing
Mar 31, 2025 4 Filing